Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sangamo Therapeutics Inc

0.7238
+0.02513.59%
Post-market: 0.7100-0.0138-1.91%19:53 EDT
Volume:5.50M
Turnover:3.91M
Market Cap:162.65M
PE:-1.04
High:0.7379
Open:0.6948
Low:0.6762
Close:0.6987
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
More
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h

US Stocks Likely To Open Lower After The Worst Selloff Since 2020: Tariff Announcement Was '100% Smoot Hawley Disguised As Thoughtful Policy,' Says Expert

Benzinga
·
04 Apr

Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday

Benzinga
·
04 Apr

Stocks to Watch: Pamt, CXApp, Sangamo Therapeutics

Dow Jones
·
03 Apr

BRIEF-Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System

Reuters
·
03 Apr

Shares of Sangamo Therapeutics Rally on Licensing Deal With Eli Lilly

Dow Jones
·
03 Apr

Sangamo Signs Capsid License Deal With Eli Lilly; Shares Rise After Hours

MT Newswires Live
·
03 Apr

Sangamo Therapeutics Enters Capsid License Agreement With Lilly

Dow Jones
·
03 Apr

Sangamo: Agreement Grants Lilly Rights to Employ Co's Novel Proprietary Capsid, Stac-Bbb, for up to 5 Potential Disease Targets

THOMSON REUTERS
·
03 Apr

Sangamo Therapeutics Inc: Eligible to Earn up to $1.4 Bln in Additional Licensed Target Fees and Milestone Payments

THOMSON REUTERS
·
03 Apr

Sangamo Therapeutics Inc: Sangamo to Receive an $18 Mln Upfront License Fee

THOMSON REUTERS
·
03 Apr

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

THOMSON REUTERS
·
03 Apr

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Business Wire
·
03 Apr

Truist Removes Price Target From Sangamo Therapeutics, Keeps Buy Rating; Price Target Had Been $5

MT Newswires Live
·
19 Mar

Sangamo Therapeutics Price Target Maintained With a $2.00/Share by RBC Capital

Dow Jones
·
18 Mar

IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday

Benzinga
·
18 Mar

Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
17 Mar

Sangamo Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
17 Mar

Sangamo Therapeutics Q4 2024 GAAP EPS $(0.11) Misses $(0.08) Estimate, Sales $7.551 Miss $13.617M Estimate

Benzinga
·
17 Mar

BRIEF-Sangamo Therapeutics Q4 EPS USD -0.11 Vs. IBES Estimate USD -0.09

Reuters
·
17 Mar

Sangamo Therapeutics Q4 Operating Expenses USD 33.5 Million

THOMSON REUTERS
·
17 Mar

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."